DiscoverPeerVoice Oncology & Haematology VideoElizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer
Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer

Update: 2024-09-23
Share

Description

Visit https://www.peervoice.com/SKB860 to view the entire programme with slides. After completing “Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer”, participants will be able to: Discuss the need for early identification of relapse or disease progression in patients with HER2+ gastric/gastroesophageal junction (GEJ) cancer who are receiving HER2-targeted therapy; Identify how approved and investigational antibody-drug conjugate (ADC) therapies for HER2+ gastric/GEJ cancer are differentiated, based on clinical data and line of therapy; Explain the rationale for retesting HER2-positivity in patients with gastric/GEJ cancer who have progressed on HER2-targeted therapy; and Propose evidence-based treatment plans for patients with HER2+ gastric/GEJ cancer who have progressed on HER2-targeted therapy, based on patient and disease characteristics.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer

PeerVoice